Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(28 sites)
United States
Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona USC Norris Comprehensive Cancer Center, Los Angeles, California Yale Comprehensive Cancer Center, New Haven, Connecticut Norton Cancer Institute - Norton Healthcare Pavilion, Louisville, Kentucky John Theurer Cancer Center, Hackensack, New Jersey MD Anderson Cancer Center, Houston, Texas Next Oncology-Oncology, San Antonio, Texas NEXT Oncology Virginia, Fairfax, Virginia France
Institut Gustave Roussy (IGR), Villejuif Hong Kong
Prince of Wales Hospital (PWH) - The Chinese University of Hong Kong (CUHK), Hong Kong, Hong-Kong Italy
Ospedale San Raffaele, IRCCS - Oncologia Medica, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, Milan IEO - Istituto Europeo di Oncologia, IRCCS, Milan Netherlands
Radboudumc - Centrum voor Oncologie, Nijmegen Singapore
National University Hospital (NUH) - Medical Oncology, Singapore National Cancer Centre Singapore (NCCS), Singapore Spain
Hospital HM Nou Delfos, Barcelona Vall d'Hebron University Hospital, Barcelona See outside Hospital Universitario Reina Sofia, Córdoba Virgen of Arrixaca University Clinical Hospital, El Palmar Ramón y Cajal Hospital, Madrid Hospital Universitario Fundación Jiménez Díaz, Madrid HM Sanchinarro University Hospital, Madrid University Hospital Quironsalud Madrid, Madrid Hospital universitario virgen macarena, Seville San Juan de Reus University Hospital, Tarragona Hospital Clinico Universitario de Valencia, Valencia La Fe University and Polytechnic Hospital, Valencia